The stock of MEI Pharma, Inc. (NASDAQ:MEIP) has been Initiated to Buy by H.C. Wainwright in its latest research note that was published on December 20. MEIP was given a price target of $10, with other Wall Street analysts also giving their reports regarding the stock. H.C. Wainwright, analysts launched coverage of MEIP stock with a Buy rating, according to their flash note to investors on December 20. Analysts at Stifel issued an upgrade fromHold to Buy for the stock, in a research note that dated back to July 27.
MEI’s stock is covered by 8 analysts, with 4 of them rating the stock as Buy. It has been deemed to have strong buy by 4 of the analysts, none of them have rated it as a Hold while none of them rated it as sell. The situation was different a month ago when the stock was rated as a Buy by only 4 analysts. 4 of them rated it as strong buy with none of them recommended investors to Hold on to the stock. Meanwhile, none analyst(s) rated it as a sell. The above data shows that MEIP has an average analyst rating of 1.50.
MEI Pharma, Inc., which has current market capitalization of above $118 Million, published its last quarter earnings on March 31, 2019. The company was able to amass $1.25 million in revenue. This figure is $0.56 million more than what analysts had expected which was $0.69 million.
MEI has around 7 Billion cash on their books at the moment. This figure will have to be compared and looked into, with their current liabilities standing at $12 Billion. The MEI stock is bringing in revenue of over 12 months, which is roughly 1 Billion. Despite all that, MEI Pharma, Inc. is seeing things progressing very much as their y-o-y quarterly revenue surged by 188.45%.
Looking at the stock’s Technical analysis information over the past 50 days shows that its Raw Stochastic average stood at 4.9%. This figure is worse than the company’s 20-day Raw Stochastic average which currently stands at 12.07%. Over the past 20 days, MEI’s Stochastic %K stood at 6.31% while its Stochastic %D was revealed to be 7.98%.